Clinical Trials Browser

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT06657144 2026-04-06

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Phase 1 Recruiting

48 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT00980460 2026-03-31

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Phase 3 Active not recruiting

236 enrolled 18 charts

Gastrointestinal

PRETEXT I Hepatoblastoma

NCT07397338 2026-03-30

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1/2 Recruiting

370 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07036380 2026-03-27

TACTIC

Phase 2 Recruiting

75 enrolled

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT05771480 2026-03-25

TOURMALINE

Phase 3 Active not recruiting

142 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

286 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06535607 2026-03-24

eVOLVE-02

Phase 2 Recruiting

257 enrolled

GastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT07490002 2026-03-24

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

Phase 2 Not yet recruiting

33 enrolled

Gastrointestinal

Esophageal Squamous Carcinoma

NCT06917079 2026-03-23

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

387 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07392541 2026-03-23

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

Phase 1/2 Recruiting

29 enrolled

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT07481058 2026-03-20

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Clinical Trials

HERIZON-GEA-01

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

DESTINY-BTC01

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

KEYNOTE-966

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

SKYSCRAPER-08

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

PIPAC in Gastric Peritoneal Metastasis

innovaTV 207

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

TACTIC

TOURMALINE

KEYNOTE-966

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

eVOLVE-02

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer